Product Information
IMATINIB MESYLATE 100 MG TAB is a generic product labeled by Quallent Pharmaceuticals Health LLC, priced at $0.6243 per EA under NDC 82009008690. Its NADAC has been published 149 times since Nov 29, 2023.
FDA first approved this application on Jul 23, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/1
Manufacturer
Quallent Pharmaceuticals Health LLCNDC
82009008690
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IMATINIB MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA212773FDA Approved
7/23/2020
TE Code
AB
On Market Since
9/1/2023
Pharmacological Classes
Price Statistics
The NADAC for IMATINIB MESYLATE 100 MG TAB has been published 149 times since Nov 29, 2023, and over the history we have for it it has risen 2.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6243 per EA |
|---|---|
| All-time high | $0.9761 (Sep 10, 2025) |
| All-time low | $0.3890 (May 22, 2024) |
| 52-week high | $0.9248 |
| 52-week low | $0.6114 |
| Median price | $0.6678 |
| Average price | $0.7085 |
| Largest weekly change | -35.6% (May 22, 2024) |
| Weeks tracked | 149 |
| Tracking since | Nov 29, 2023 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Quallent Pharmaceuticals Health LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Imatinib Mesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMATINIB MESYLATE 100 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 100 MG TAB, manufactured by Quallent Pharmaceuticals Health LLC, is $0.6243 per EA (NDC 82009008690), effective Sep 30, 2026.
How has the price of IMATINIB MESYLATE 100 MG TAB changed over time?
Over the history we have for it, the NADAC for IMATINIB MESYLATE 100 MG TAB has risen 2.6%. It has been tracked across 149 weekly CMS publications since Nov 29, 2023.
What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 100 MG TAB?
Since Nov 29, 2023, the NADAC for IMATINIB MESYLATE 100 MG TAB has ranged from a low of $0.3890 (May 22, 2024) to a high of $0.9761 (Sep 10, 2025), with a median of $0.6678 per EA.
Are there cheaper alternatives to IMATINIB MESYLATE 100 MG TAB?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as IMATINIB MESYLATE 100 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures IMATINIB MESYLATE 100 MG TAB?
IMATINIB MESYLATE 100 MG TAB (NDC 82009008690) is labeled by Quallent Pharmaceuticals Health LLC, and CMS classifies it as a generic product.